AbbVie (ABBV) Capital Expenditures (2012 - 2026)

AbbVie (ABBV) has 15 years of Capital Expenditures data on file, last reported at $265.0 million in Q1 2026.

• Quarterly Capital Expenditures rose 12.77% year-over-year to $265.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 22.44% YoY) and the FY2025 annual result came in at $1.2 billion, up 24.64% from the prior year.
• Capital Expenditures eased to $265.0 million in Q1 2026 per ABBV's latest filing, from $329.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $381.0 million in Q3 2025 and bottomed at $143.0 million in Q2 2022.
• The 5-year median for Capital Expenditures is $219.0 million (2023), against an average of $230.9 million.
• The widest annual swing landed in 2022, when Capital Expenditures decreased 26.67%; it then surged 53.01% in 2025.
• Tracing ABBV's Capital Expenditures over 5 years: stood at $213.0 million in 2022, then fell by 3.76% to $205.0 million in 2023, then soared by 41.95% to $291.0 million in 2024, then rose by 13.06% to $329.0 million in 2025, then declined by 19.45% to $265.0 million in 2026.
• Per Business Quant, the three latest ABBV Capital Expenditures figures stand at $265.0 million (Q1 2026), $329.0 million (Q4 2025), and $381.0 million (Q3 2025).

Peer Comparison